Skip to content
lifestyle.nextmentors.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oryzon Genomics, S.A.
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
November 4, 2026
Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
November 3, 2026
ORYZON to participate in upcoming events in November
October 28, 2026
ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant
October 15, 2026
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
September 28, 2026
ORYZON to Participate in Upcoming Events in September and October
September 10, 2026
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
August 31, 2026
ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026
July 27, 2026
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
June 11, 2026
ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
June 2, 2026
1
2
Next Page
→